Abbott Laboratories' medical device business is executing well, with double-digit growth in structural heart and diabetes.
The decision to allow a new trial could have implications for both the companies and families with babies born prematurely.
Today, Benzinga 's options scanner spotted 10 uncommon options trades for Abbott Laboratories. This isn't normal. The overall ...
We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...
Zacks.com on MSN1d
Abbott Laboratories Gains 12.7% in a Year: What's Driving the Stock?ABT's shares rise on the back of its diversified business portfolio. However, the unfavorable macroeconomic scenario is concerning.
Abbott Laboratories (NYSE:ABT – Free Report) had its price objective boosted by The Goldman Sachs Group from $138.00 to ...
Infant formula makers Abbott and Reckitt saw their stocks decline Friday after a judge ruled plaintiffs could pursue a new ...
Abbott Laboratories is undervalued with strong growth in diabetes care and weight-loss markets. Discover why ABT stock is a ...
JD.com, Eli Lilly and Company, Abbott Laboratories, Veeva Systems, and Johnson & Johnson are the five Pharmaceutical stocks to watch today, according to MarketBeat’s stock screener tool.
GlobalData on MSN1d
Reckitt’s Mead Johnson, Abbott to face new trial in US infant-formula caseReckitt Benckiser’s Mead Johnson unit and Abbott Laboratories have been ordered to face a new trial in the US over ...
Today, Benzinga's options scanner spotted 11 options trades for Abbott Laboratories. This is not a typical pattern. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback